AD
ADMA Biologics
ADMA · NASDAQ
$9.62 +2.01% (+$0.19)
1M -1.33%
Market Cap $2.23B
P/E Ratio 13.20x
Div. Yield -
ROE 39.59%
Bulios Fair Price
$6.44
33.1% downside
Current Price
$9.62
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ADMA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
70 /100
Cheap P/E 13.20x
EV/EBITDA 9.78x
P/FCF 19.14x
Growth
100 /100
Growing Rev. growth 49.05%
Book val. growth 46.45%
EPS growth N/A
Profitability
100 /100
Strong Gross margin 64.71%
Net margin 32.98%
FCF margin 22.74%
Quality
94 /100
Excellent ROIC 27.55%
ROE 39.59%
Asset turnover 0.75x
Debt
95 /100
Low Debt/Equity 0.50x
Current ratio 6.97x
Net debt/EBITDA 0.29x
Stability
42 /100
Moderate Beta 0.77x
Rev. volatility 27.01%
Profitable years 2
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ADMA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Adam S. Grossman
Employees
644
Headquarters
Ramsey
Upcoming events
04 NOV
Earnings
Upcoming earnings report